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Introduction: Alzheimer’s disease (AD) is associated with the accumulation of β-amyloid (Aβ) as senile plaques in
the brain, thus leading to neurodegeneration and cognitive impairment. Plaque formation depends not merely on
the amount of generated Aβ peptides, but more importantly on their effective removal. Chronic infections with
neurotropic pathogens, most prominently the parasite Toxoplasma (T.) gondii, are frequent in the elderly, and it has
been suggested that the resulting neuroinflammation may influence the course of AD. In the present study, we
investigated how chronic T. gondii infection and resulting neuroinflammation affect plaque deposition and removal
in a mouse model of AD.
Results: Chronic infection with T. gondii was associated with reduced Aβ and plaque load in 5xFAD mice. Upon
infection, myeloid-derived CCR2hi Ly6Chi monocytes, CCR2+ Ly6Cint, and CCR2+ Ly6Clow mononuclear cells were
recruited to the brain of mice. Compared to microglia, these recruited mononuclear cells showed highly increased
phagocytic capacity of Aβ ex vivo. The F4/80+ Ly6Clow macrophages expressed high levels of Triggering Receptor
Expressed on Myeloid cells 2 (TREM2), CD36, and Scavenger Receptor A1 (SCARA1), indicating phagocytic activity.
Importantly, selective ablation of CCR2+ Ly6Chi monocytes resulted in an increased amount of Aβ in infected mice.
Elevated insulin-degrading enzyme (IDE), matrix metalloproteinase 9 (MMP9), as well as immunoproteasome
subunits β1i/LMP2, β2i/MECL-1, and β5i/LMP7 mRNA levels in the infected brains indicated increased proteolytic
Aβ degradation. Particularly, LMP7 was highly expressed by the recruited mononuclear cells in the brain,
suggesting a novel mechanism of Aβ clearance.
Conclusions: Our results indicate that chronic Toxoplasma infection ameliorates β-amyloidosis in a murine
model of AD by activation of the immune system, specifically by recruitment of Ly6Chi monocytes and by
enhancement of phagocytosis and degradation of soluble Aβ. Our findings provide evidence for a modulatory
role of inflammation-induced Aβ phagocytosis and degradation by newly recruited peripheral immune cells in
the pathophysiology of AD.
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Alzheimer’s disease (AD) is the most prevalent cause of
dementia in the elderly, affecting more than 15 million
people worldwide [1]. Although AD was first described
more than a century ago, the exact pathomechanisms of
this disorder are still not fully understood. According to
the widely accepted amyloid cascade hypothesis [2], the
amyloid precursor protein (APP) is cleaved by β- and γ-
secretases, and the resulting Aβ40 and Aβ42 peptides ac-
cumulate as fibrils and plaques, due to their highly
hydrophobic nature [3–5]. However, in aging individuals
and in AD patients it is not overproduction, but reduced
clearance of β-amyloid (Aβ) that is thought to contribute
to disease progression [6]. Specific transporters at the
blood–brain barrier were discovered to transport Aβ
and their insufficient function leads to intracerebral Aβ
accumulation and plaque formation [7–10]. Clearance
by the brain’s phagocytic system is also known to play
an important role in limiting disease progression. At
first, microglia cells become activated, but later fall into
a state of senescence, thus failing to effectively remove
intracellular and extracellular Aβ – a development that
is paralleled by ongoing neuroinflammation [11–13]. Ul-
timately, severe neurodegeneration leads to cognitive im-
pairments and behavioral alterations [14].
The role of innate immune cells has been discussed ex-
tensively in an attempt to untangle their beneficial and
detrimental contributions in brain homeostasis and path-
ology [15–18]. Previously, all phagocytic cells in the brain
have been termed “microglia”, until it recently became
evident that resident microglia develop from yolk sac
macrophages and populate the CNS during early fetal de-
velopment [19], whereas distinct populations of bone
marrow-derived mononuclear cells can enter the adult
CNS under inflammatory and even under steady-state
conditions [20–22]. Furthermore, infiltrating myeloid-
derived Ly6Chi CCR2+ monocytes also give rise to brain
macrophages [17, 23–25]. Subsequent differentiation of
resident and recruited innate immune cells has revealed
distinct contributions of each subset under various
pathological conditions [22]. Resident microglia accu-
mulate directly around Aβ plaques, and contribute to
Aβ clearance in the early phase of AD development.
Later on, their role becomes a detrimental one, as they
promote neurodegeneration by pro-inflammatory
cytokine production [26]. Interestingly, bone marrow-
derived mononuclear cells recruited to the CNS con-
tribute to repair after spinal cord injury [27] as well as
Aβ uptake and plaque elimination [28–30].
Several studies have described that AD is exacerbated
by repeated or chronic systemic inflammation as well as
by several infections in humans and different murine
models [31–36]. It has even been speculated that specific
pathogens may be causative in AD [37, 38]. The mostcommon sporadic form of AD primarily occurs in the
elderly, and older age is also associated with elevated
susceptibility to infectious diseases [39], and an in-
creased probability of having accumulated dormant in-
fections, including toxoplasmosis [40–42].
Toxoplasmosis, caused by the obligate intracellular
protozoan parasite Toxoplasma (T.) gondii, is a worldwide
zoonosis with high medical relevance [40]. Serologic
prevalence data suggest that the geographical distribution
of the infection varies between 20 and 90 %, depending
mainly on culinary habits and hygiene. Moreover, the in-
fection rate strongly increases with age [43], as latent
T. gondii infection is associated with lifelong parasite per-
sistence and typically remains clinically asymptomatic in
immunocompetent individuals. However, recent studies –
by our laboratory and others – indicate an ongoing basal
inflammation in the CNS following chronic T. gondii in-
fection in rodents [44–46]. The subtle neuromodulatory
capacity of the parasite in humans and mice has also been
an area of recent investigation [47]. Prominent features of
cerebral toxoplasmosis in animal models are the activation
of glia and recruitment of peripheral immune cells to the
CNS [18, 48, 49]. Recruited Ly6Chi monocytes co-
expressing C-C chemokine receptor type 2 (CCR2) [50] are
critical to governing acute and chronic stages of infection
[18, 23, 51–53]. Principally, we have recently described the
contribution of Ly6Cint monocyte-derived dendritic cells
and Ly6Clow monocyte-derived macrophages to parasite
control upon chronic toxoplasmosis in the CNS [23].
The role of T. gondii in the development and course of
AD is currently debated. Kusbeci et al. reported increased
seroprevalence of anti-T. gondii IgG in a small group of
AD patients, suggesting an implication of the parasite in
AD pathogenesis [54], but these findings could not be rep-
licated in another study [55]. Animal studies have sug-
gested that T. gondii infection may actually be able to
prevent neurodegeneration [56, 57] and can even reduce
plaque burden and prevent memory decline [58]. The lat-
ter studies suggest that T. gondii may actually play a pro-
tective rather than a detrimental role in AD. However,
they do not address the underlying mechanisms of plaque
reduction. In the present study, we investigated how AD
progression is influenced by the boosted presence of mye-
loid cells in the CNS in latent toxoplasmosis.
Our data reveal that upon chronic Toxoplasma infection,
recruited mononuclear cells are capable of ameliorating
plaque burden in a murine model of cerebral β-amyloidosis
through Aβ phagocytosis and increased degradation.
Materials and methods
Animal models
All animal experiments were approved according to
German and European legislation by the local au-
thorities. Experiments were conducted with 8 weeks
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mice (5xFAD/Tg6799 strain (B6SJL-Tg(APPSwFlLon,
PSEN1*M146L*L286V) 6799Vas/Mmjax backcrossed
for >10 generations to C57BL/6J, JAX stock#006554)
[59, 60]. In this model, Aβ plaques in the brain are
detectable from the age of 50 days and their number
increases by age [61]. At least five animals per group
in up to two independent experiments were used.
T. gondii infection
T. gondii cysts of the ME49 type II strain were used for
this study. Parasites were harvested from the brains of
female NMRI mice infected intraperitoneally (i. p.) with
T. gondii cysts 4 to 5 months earlier. Brains obtained
from infected mice were mechanically homogenized in
1 mL sterile phosphate-buffered saline (PBS) and the
cysts were counted using a light microscope. Two cysts
were administered i. p. into 8-week-old mice in a total
volume of 200 μL. This time point was chosen because
at the age of 8 weeks, animals are fertile and are consid-
ered adults in this respect.
Monocyte depletion
To specifically ablate CCR2+Ly6Chi monocytes, 66 μg of
anti-CCR2 antibody (clone MC-21, provided by M.
Mack, University of Regensburg) were administered i. p.
on d15, d18, d21, d24 and d27 post infection. Control
mice received PBS. On d22 (12-15 h post antibody injec-
tion), blood was collected retro-orbitally to confirm de-
pletion. Mice were sacrificed and samples were collected
on d28.
Blood and brain sampling
At the chronic stage of infection (8 weeks post infection
and 4 weeks post infection for depletion and phagocyt-
osis assays, see below), mice were deeply anesthetized
and if necessary blood was drawn from the inferior vena
cava using a 26G needle and syringe. Subsequently, mice
were perfused intracardially with 60 ml sterile ice-cold
PBS. Brains were removed and prepared accordingly for
further analysis.
Histopathology
Brain hemispheres were removed and immersed in 4 %
paraformaldehyde (PFA) for several days. Paraffin-
embedded, 4 μm thick sections were deparaffinized and
conventionally stained with hematoxylin-eosin (H&E)
stain. Immunohistochemical analysis was performed ac-
cording to our previous publications [12, 13, 62–66]
using a BOND-MAX (Leica Microsystems GmbH/
Menarini, Germany) with antibodies against Aβ (clone
4G8, Chemicon, Germany), ionized calcium-binding
adapter molecule 1 (IBA1, Wako 019–19741, Germany)
to label microglia, glial fibrillary acid protein (GFAP,DAKO Z033401, Germany) to label astrocytes, NeuN
(Millipore MAB377, Germany) to label neurons, and
anti-Toxo (Dianova DLN-16734, Germany) to label T.
gondii. Slides were developed using the BondTM Polymer
Refine Detection kit (Menarini/Leica, Germany). For the
evaluation whole tissue sections were digitized at
230 nm resolution using a MiraxMidi Slide Scanner
(ZeissMicroImaging GmbH, Germany) [67].
Immunofluorescence analysis
For immunofluorescent staining, coronal brain sections
(16 μm) were prepared with a cryomicrotome (Leica,
Germany). Immunolabeling with antibodies against Aβ
(4G8, Chemicon, Germany), Iba1 (polyclonal, Wako)
and Ly6C (ER-MP20, Acris Antibodies, Germany) were
performed overnight at 4 °C after 2 min pretreatment
with 98 % formic acid. Secondary antibodies goat anti-
rat (Alexa Fluor 488, 1:200, Invitrogen, Germany), goat
anti-rabbit (Alexa Fluor 488, Invitrogen, Germany) and
goat anti-mouse (Alexa Fluor 594, Invitrogen, Germany)
were used. Free floating sections were mounted with
ProLong Gold with DAPI (life technologies, Germany).
A Zeiss (Carl Zeiss, Germany) microscope equipped
with an AxioCam HRc 3 digital camera and AxioVision
4 Software were used to analyze staining and obtain
images.
Quantification of Iba1 and Ly6C association with
plaques was performed using the ImageJ plot profile
function (http://imagej.nih.gov/ij/). For this purpose,
two perpendicular fluorescence profiles spanning
400 μm and centered over the plaques were measured
in immunofluorescence stainings. At least 30 plaques
from at least four different tissue sections were
analyzed.
Two-Photon image acquisition and analysis
For in vivo staining of amyloid plaques, mice were i. p.
injected with 10 mg kg−1 methoxy-X04 (Tocris Bio-
science) in 5 % DMSO/95 % NaCl (0.9 %) 12 h before
brain harvesting and two-photon image acquisition.
Brains were placed under microscopy coverslips for ex
vivo microscopy using a Zeiss LSM 710 (Carl Zeiss, Jena,
Germany) equipped with a MaiTai DeepSee 2-Photon
laser (Spectra-Physics, Darmstadt, Germany) tuned at
800 nm. Fluorescence emission was split using dichroic
mirrors and detected using non-descanned detectors.
Methoxy-X04 fluorescence was read out at 450-490 nm.
Fluorescence signal acquired above 520 nm was consid-
ered autofluorescence. Confocal stacks spanning at least
50 μm were collected with a z-spacing of 4 μm using a
W Plan-Apochromat 20x water immersion objective
with a numerical aperture of 1.0.
Images were processed and superimposed using the
Imaris (Version 7.7., Bitplane, Zürich, Switzerland)
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with blood vessels (identified by different tissue autoflu-
orescence) were manually excluded from the analysis.
Plaques were automatically detected and quantified in
three dimensions using the measurement package of the
Imaris software.
Enzyme-linked immunosorbent assay (ELISA) and
preparation of protein extracts
Freshly harvested brain tissue was snap-frozen in liquid
nitrogen and stored at −80 °C. Aβ42 was quantified in
whole brain hemispheres by ELISA against human Aβ42
(Thermo Fisher Scientific, Germany). For total Aβ42
quantification, brains were homogenized in 5 M guan-
idine hydrochloride buffer (GuHCl) (5 M GuHCl in
50 mM Tris/HCl, pH 8.0) and incubated for 4 h at room
temperature on a shaker. For discrimination between
small (soluble) and large (insoluble) Aβ42 aggregates,
brains were homogenized in carbonate buffer (100 mM
Na2CO3 in 50 mM NaCl, pH 11.5, 20 μl/mg) and centri-
fuged. The supernatant was mixed with 8 M GuHCl (in
82 mM Tris/HCl, 0.6 ml GuHCl/1 ml carbonate buffer)
to obtain the soluble Aβ42 fraction. The pellet was dis-
solved in 5 M GuHCl (10 μl/mg) and incubated 3 h at
RT on a shaker to obtain the insoluble Aβ42 fraction.
Prior to ELISA analysis, each extract (total, soluble and
insoluble) was diluted with BSAT-PBS (5 % bovine
serum albumin in PBS with 0.03 % Tween-20 and prote-
ase inhibitor (Roche, Germany)) according to the ex-
pected Aβ42 content. ELISA was then performed
according to the manufacturer’s instructions.
RT-PCR from whole-brain homogenates
After removal, tissue samples from brains were immedi-
ately transferred to RNA later (QIAgen, Germany). Total
RNA was isolated as previously described with the peq-
GOLD HP Total RNA Kit (peqlab, Germany) including
an on-membrane DNase I digestion (peqlab, Germany)
[18].
Relative gene expression was determined similar to
previous descriptions [18, 68] using TaqMan® RNA-to-
CT
TM 1-Step Kit (life technologies, Germany). Reactions
were developed in a LightCycler® 480 Instrument II
(Roche, Germany). Reverse transcription was performed for
15 min at 48 °C followed by 10 min at 95 °C. Subsequently,
45 amplification cycles were run, comprising of denatur-
ation at 95 °C for 15 s and annealing/elongation at 60 °C
for 1 min. TaqMan® Gene Expression Assays (life technolo-
gies, Germany) were used for mRNA amplification of
HPRT (Mm01545399_m1), IDE (Mm00473077_m1),
(IL10, Mm00439616_m1), MMP9 (Mm00442991_m1),
NEP (MME, Mm00485028_m1), PSMB8/LMP7 (Mm00
440207_m1), PSMB9/LMP2 (Mm00479004_m1) and
PSMB10/MECL-1 (Mm00479052_g1). HPRT mRNAexpression was chosen as reference for normalization
and target/reference ratios were calculated with the
LightCycler® 480 Software release 1.5.0 (Roche,
Germany). Resulting data were further normalized to
values of appropriate control groups.
RT-PCR from sorted cell populations
Isolated brain single cell suspensions were surface
stained as described below and sorted on a BD FACSAr-
iaTM III. After sorting, cells were pelleted, any remaining
liquid was removed and cells were frozen at −80 °C.
Total RNA was isolated using the RNeasy® Mini Kit
(QIAgen, Germany). cDNA was synthetized with the
iScript™ cDNA Synthesis Kit (BIO-RAD, Germany).
Relative gene expression was measured using the Taq-
Man® Universal PCR Master Mix (Applied Biosystems,
Germany). TaqMan® Gene Expression Assays (life tech-
nologies, Germany) and data analysis was the same as
for RT-PCR from whole-brain homogenates.
Cell isolation
For mononuclear cell isolation brains were homogenized
in a buffer containing 1 M Hepes pH 7.3 and 45 %
glucose and then sieved through a 70 μm strainer as pub-
lished previously [18]. The cell suspension was washed
and re-suspended in 10 mL 75 % Percoll (GE Healthcare,
Germany) in PBS and over layered with 10 mL 25 % Per-
coll in PBS and 5 mL PBS. The gradient was centrifuged
for 45 min at 800 g without brake. Cells were recovered
from the 25 %/75 % interphase, washed and used immedi-
ately for further experiments.
Surface staining
Single cell suspensions were incubated with an anti-
FcγIII/II receptor antibody (clone 93) to block unspecific
binding and Zombie VioletTM (Biolegend, Germany), a
fixable viability dye. Thereafter, cells were stained with
fluorochrome conjugated antibodies against cell surface
markers: CD45 (30-F11, eBioscience, Germany), CD11b
(M1/70, eBioscience, Germany), Ly6G (1A8, BD Biosci-
ences, Germany), Ly6C (HK1.4, eBioscience, Germany),
CCR2 (475301, R&D, USA), TREM2 (237920, R&D,
USA), CD36 (HM36, Biolegend, Germany), in FACS buf-
fer (PBS containing 2 % FCS and 0.1 % NaN3) for
30 min on ice and then washed and fixed in 4 % parafor-
maldehyde (PFA) for 10 min.
Ex vivo phagocytosis assay
Animals were sacrificed 4 weeks post infection and sin-
gle cell suspensions were prepared as described above.
Live cells remained unstained by the Zombie VioletTM
(Biolegend, Germany) viability dye and were sorted on a
BD FACSAriaTM III. 150,000 cells were seeded into each
well of a 96-well round bottom plate and allowed to
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and 70 % humidity) before HiLyte FluorTM 488-labeled,
HFIP monomerized Aβ42 (Eurogentec, Belgium) was
added to a final concentration of 500nM. Cells were in-
cubated for 6 h, washed, surface stained and measured
by conventional and imaging flow cytometry.
Conventional flow cytometry
Cell acquisition was performed on a BD FACS CantoTM
II flow cytometer. Data were analyzed using FlowJo soft-
ware (TreeStar).
Imaging flow cytometry
Data were acquired with FlowSightTM (EMD Millipore,
USA) with a 20x objective and analyzed using IDEAS
software version 6.0. At least 52,000 (control animals) or
500,000 (T. gondii infected animals) cells were acquired
for each sample and gated to select images with single
cells in good focus (by bright field area/aspect ratio and
gradient root mean square of the bright-field image, re-
spectively). To analyze internalization, the erode mask
was used on the bright field picture of Aβ+ cells to re-
move 2 pixels from the edges of the starting mask and
to define the inner part of the cell. Then, the internaliza-
tion feature was used to define the ratio of intensity of
the Aβ signal between the inside of the cells (defined by
the erode mask) and the intensity of the total cell. While
cells with little internalization have negative scores, cells
with high internalization have positive scores. Here, an
internalization > 0 was defined as intermediate to high
internalization. Compensation matrix generated by sin-
gle-color compensation controls was used to correct
spectral overlap. Representative pictures from cell popu-
lations were chosen.
Statistical analysis
Results are presented as mean + standard error of the
mean (SEM). Statistical analysis was performed with
Prism version 6 (GraphPad Software, USA). Different
tests were used to compare values, namely Mann–Whit-
ney U test (plaque numbers and volume), Fisher’s LSD
test (results with multiple comparisons) and Student’s t
test (results with one comparison). p values of p ≤ 0.05
were considered statistically significant.
Results
T. gondii infection reduces the plaque burden in 5xFAD
mice
Infection with T. gondii led to reduced plaque burden as
determined by immunohistological staining of Aβ plaques
in 5xFAD mice (Fig. 1a and a’). Quantification revealed
significantly lower plaque numbers in the cortex of mice
infected with T. gondii as compared to transgenic control
mice (control 21.9 plaques/mm2, T. gondii 5.9 plaques/mm2, p < 0.006, Fig. 1b). This observation was further
confirmed by in situ two-photon microscopy, which was
technically restricted to the observation of cortical layers I
and II (Fig. 1c and c’). Here, methoxy-X04 stained plaque
volumes of the remaining amyloid plaques were signifi-
cantly reduced in T. gondii infected animals (controls
1548 ± 205 μm3,T. gondii 466 ± 92 μm3, p < 0.002, Fig. 1d).
Using morphological methods, we detected substantial
changes in the cortex and subcortical regions of infected
mice such as inflammatory lesions (Fig. 2a’), extensive
ionized calcium-binding adapter molecule 1 (Iba1)-re-
activity (Fig. 2b’), due to the activation of microglia and
myeloid cell infiltration, as well as glial fibrillary acid
protein (GFAP)-positive astrogliosis (Fig. 2c’). Non-
infected 5xFAD mice presented with known brain hist-
ology (Fig. 2a) and only minor activation of resident glia
cells (Iba1 and GFAP staining, Fig. 2b, c) [59]. Specific
immunodetection for neurons (NeuN labeling) revealed
no alterations in the number of neurons in the cortex of
infected versus control mice (Fig. 2d, d’). The slightly
darker shading in the infected brain is due to increased
background staining as previously seen in this infection
model in wildtype C57BL/6J mice [18]. Occasionally,
T. gondii cysts were detectable (Fig. 2a, inset).
Noting the vast activation of microglia and astrocytes
in the infected animals, we have to potentially take into
account additional specific and unspecific immuno-
logical responses as further factors for the reduction of
Aβ [69, 70].
Recruited monocytes express high CCR2, intermediate
TREM2 and CD36
Activation of resident microglia is complemented by re-
cruitment of immune cells from the periphery to the
CNS. Collectively, resident and recruited cells form a ro-
bust immune response to control T. gondii [18]. Among
recruited immune cells, the myeloid compartment plays
an important role in cerebral toxoplasmosis [71–73]. In
the following, we focused our analysis on three subsets of
myeloid-derived CD45hi CD11bhi Ly6Gneg CCR2+ mono-
nuclear cells, the CCR2hi Ly6Chi monocytes, Ly6Cint cells
and Ly6Clow macrophages (gating strategy depicted in
Fig. 3a, a’). These subsets of myeloid cells were chosen be-
cause age-related defects in the Ly6Chi monocyte popula-
tion have been linked to cognitive decline in a murine AD
model [74]. First, we detected increased numbers of
engrafted Ly6Chi, Ly6Cint and Ly6Clow cells in the brains
of T. gondii infected 5xFAD mice compared to non-
infected mice (Fig. 3a, a’).
Subsequently, we determined the expression of certain
phagocytosis-related surface molecules and quantified the
MFI by flow cytometry: Triggering Receptor Expressed on
Myeloid cells 2 (TREM2), CD36, and Scavenger Receptor
A1 (SCARA1). We compared their expression on resident
Fig. 1 T. gondii infection leads to reduced plaque burden in 5xFAD mice. a, a’ show representative cortex regions with immunohistochemical
labeling against Aβ from (a) non-infected and (a’) T. gondii infected 5xFAD mice. Arrow heads point towards remaining plaques in infected animals.
Scale bars represent 1000 μm (left) and 200 μm (right). b Quantification of cortical Aβ plaques. Data is displayed as mean ± SEM. Significance as
determined by unpaired t test with Welsh‘s correction is indicated. **p≤ 0.01. c, c’ Ex vivo two-photon micrographs of the cerebral cortex layers I and II
of (c) control and (c’) T. gondii infected 5xFAD mice injected with Methoxy-X04. Amyloid plaques stained with Methoxy-X04 are represented in green,
autofluorescence is shown in red. One representative z-stack projection spanning at least 50 μm depth is shown for each condition. Scale bar, 100 μm.
d Plaque volume in cortical layers I and II determined from at least five ex vivo two-photon micrographs shown in (c, c’). Each symbol represents one
plaque and bars represent the mean, statistical significance is denoted by asterisks. **p≤ 0.01
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was similar for all three markers: We found the highest
expression of TREM2, CD36 and SCARA1 on
Ly6Clow F4/80hi macrophages and activated microglia and
a lower expression on Ly6Chi CCR2hi monocytes and rest-
ing microglia. Ly6Cint mononuclear cells expressed inter-
mediate amounts of TREM2, CD36 and SCARA1 on
their surface (TREM2: microglia 688 ± 25, activated
microglia 2191 ± 179, Ly6Chi 595 ± 48, Ly6Cint 1298 ± 13,
Ly6Clow 3222 ± 511, Fig. 3d; CD36: microglia 152 ± 8, acti-
vated microglia 1616 ± 281, Ly6Chi 749 ± 37, Ly6Cint 1175
± 92, Ly6Clow 1879 ± 208, Fig. 3e; SCARA1: activated
microglia 15977 ± 3220, Ly6Chi 6319 ± 1395, Ly6Cint
10805 ± 2221, Ly6Clow 14964 ± 3088, Fig. 3f).Resident microglia activation was confirmed by in-
creased CD11c, MHC I and MHC II levels as measured
by flow cytometry (data not shown). Thus, our data indi-
cate that cerebral toxoplasmosis induces the recruitment
of different myeloid-derived mononuclear cell subsets to
the CNS that may contribute to the removal of Aβ by
activated microglia.
Myeloid-derived mononuclear cells phagocytose Aβ
Resident and recruited immune cell subsets display dif-
ferent phagocytic capacity [23]. Here we compared
mononuclear cell subpopulations with respect to their
ability to specifically phagocytose Aβ42 in an ex vivo
phagocytosis assay. To this end, we freshly isolated brain
Fig. 2 T. gondii infection induces histopathological changes and activation of microglia. a, a’ Hematoxylin and eosin (H&E) stained coronal
sections from (a) non-infected and (a’) T. gondii infected 5xFAD mice. * denotes meningeal infiltrates, arrows show inflammatory foci, the arrow
head highlights a T. gondii cyst. The inset shows a cyst stained with an antibody against T. gondii. b–d’ Representative pictures of immunohistochemical
stainings against (b, b’) Iba1, (c, c’) GFAP, and (d, d’) NeuN of coronal brain sections from (b, c, d) non-infected and (b’, c’, d’) T. gondii infected 5xFAD
mice. Scale bars represent 1000 μm (left column) and 200 μm (right column)
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surveilling microglia (CD45int CD11b+), activated micro-
glia (CD45+ CD11b+) as well as Ly6Chi monocytes, Ly6Cint
and Ly6Clow cells (CD45hi CD11bhi Ly6G− Ly6Chi/int/low)
were distinguished by flow cytometric analysis. The low
ability of resident microglia to take up Aβ42 was reflected
in their low median fluorescence intensity (MFI) for Aβ42-
HiLyte Fluor 488 (1749 ± 88, Fig. 4b, green bar). Upon
T. gondii infection, microglia cells became activated, but
their Aβ42 uptake remained low (1564 ± 119, Fig. 4b, blue
bar). Notably, Ly6Chi monocytes exhibited the highest
MFI (5238 ± 239, Fig. 4b, dark red bar) suggesting greater
phagocytic capacity. Similarly, also Ly6Cint and Ly6Clow
cells were found to exhibit significantly higher MFI
compared to microglia or activated microglia (Ly6Cint
4396 ± 204, Ly6Clow 3890 ± 387, Fig. 4b, medium and
light red bars, p < 0.0001). Relative MFIs measured in
cells isolated from wildtype mice showed a similar pat-
tern, confirming that Aβ42 uptake was not restricted to
5xFAD cells (Additional file 1: Figure S1).
We further verified that the detected fluorescence re-
sulted from internalized Aβ42 rather than from surface-bound signals. Therefore, we analyzed the cells using im-
aging flow cytometry that allows obtaining images of in-
dividual cells. Gating was performed as described in
Fig. 3a and representative pictures for each popula-
tion are shown in Fig. 4c. Microglia and activated
microglia populations contained lower numbers of
Aβ+ cells (Table 1, first column). Consistent with the
previous measurements by conventional flow cytome-
try, fluorescence was low or absent in resting and ac-
tivated microglia, but all monocyte populations
showed an intense signal (Fig. 4c and Additional file 1:
Figure S1). Fluorescence was distributed equally across
the cells, sometimes with several additional bright
spots inside individual cells. This further indicated the
uptake of Aβ42 by recruited mononuclear cells
(CD45hi CD11bhi Ly6G− Ly6Chi/int/low) upon T. gondii in-
fection. Morphologically, monocytes and the other two
monocyte-derived cell subsets were more granular than
(activated) microglia, represented by higher side scatter in-
tensities (Fig. 4c and Table 1, last column). We quantified
the internalization of Aβ42 by calculating the ratio of the
fluorescence intensity within the cell to the intensity of
Fig. 3 Myeloid-derived mononuclear cells are recruited to the brain upon T. gondii infection and express phagocytosis related surface molecules.
Mononuclear cells were isolated from 5xFAD mouse brains and subjected to flowcytometric analysis. a, a’ Representative pseudocolor plots are
shown for (a) non-infected and (a’) infected 5xFAD animals and demonstrate the recruitment of CD45hiCD11bhiLy6GnegLy6C+ cells to the brain
upon T. gondii infection. After gating cells by their forward and side scatter properties, excluding doublets and dead cells (not shown), we used
CD45 and CD11b expression to discriminate between resting microglia (a, bottom elliptic gate) or activated microglia (a’, bottom elliptic gate),
respectively, and myeloid cells (a’, top elliptic gate). From myeloid cells, Ly6G+ neutrophils were excluded and the Ly6C expression of the remaining
CD11bhiLy6G− cells was used to gate Ly6Chi, Ly6Cint and Ly6Clow mononuclear cells. b–f We compared the surface expression of CCR2, F4/80, TREM2,
CD36, and SCARA1 between resting microglia, activated microglia and myeloid-derived mononuclear cell subsets. The median fluorescence intensity
(MFI) for each marker and population is displayed as mean + SEM. Significance levels (p values) determined by Fisher’s LSD test are indicated. *p≤ 0.05,
***p≤ 0.001, ****p≤ 0.0001
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to high internalization and were found in more than 97 %
of all Aβ+ cells regardless of the population (Table 1, sec-
ond column). The mean internalization varied between
populations with activated microglia being the lowest and
Ly6Chi monocytes being the highest (Table 1, third
column).
To confirm that it is indeed the recruited monocytes
and their progeny contributing to plaque removal, we
ablated Ly6Chi monocytes using a monoclonal anti-
CCR2 antibody. We chose a lower antibody concentra-
tion to only reduce monocyte numbers, because the
complete elimination would highly increase thesusceptibility of infected mice as recently described by
us [23]. One week after initiating the ablation, we de-
tected significantly reduced Ly6Chi monocyte levels in
the blood (Fig. 5a, b, c). After 2 weeks of anti-CCR2
antibody administration (28 days after infection), Ly6Chi
monocyte numbers were still significantly reduced in the
blood (Fig. 5b, c). This peripheral depletion led to a
trending reduction of Ly6Chi monocytes and Ly6Clow
monocyte-derived macrophages in the brain on day 28
after T. gondii infection (Fig. 5d). From the isolated
brains, we quantified Aβ42 by ELISA. Importantly, di-
minished Ly6Chi monocyte numbers were associated
with an increased total amount of Aβ42 in the brain of
Fig. 4 Recruited mononuclear cells are potent Aβ phagocytic cells. a–c Ex vivo phagocytosis assay was performed with mononuclear cells
isolated from 5xFAD and C57BL/6 mouse brains and cleared from dead cells by sorting via flow cytometer. a Populations were gated as
described in Fig. 3a. Representative histograms show the uptake of fluorescence labeled Aβ42 peptide by different cell populations. Gray curves
show the 4 °C control (dark gray) and the Aβ42− control (light gray) for each population. b Bars indicate the median fluorescence intensity (MFI) of
each population to express differences in the amount of Aβ42 taken up. Data are displayed as mean + SEM (n = 4-5). c Representative images
obtained with FlowSight™ are shown for each population. Scale bar, 20 μm. Significance levels (p values) determined by Fisher’s LSD test are
indicated. ns, not significant, *p ≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001
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Table 1 Quantification of Aβ42 uptake by imaging flow cytometry
Population Aβ + cells ratio > 0 Mean ratio Mean side scatter intensity
Microglia 77.8 ± 2.5 % 99.3 ± 0.2 % 5.0 ± 0.1 1916 ± 85
Activated microglia 71.8 ± 2.3 % 97.1 ± 0.2 % 3.0 ± 0.02 1161 ± 35
Ly6Chi 99.4 ± 0.09 % 99.8 ± 0.02 % 5.4 ± 0.06 3574 ± 143
Ly6Cint 96.1 ± 0.5 % 99.4 ± 0.1 % 5.0 ± 0.1 3376 ± 130
Ly6Clow 92.8 ± 0.8 % 99.0 ± 0.05 % 4.8 ± 0.08 3107 ± 93
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T. gondii + anti-CCR2 414 ± 75 ng/ml, Fig. 5e).
While immunohistological methods (Fig. 1) can only
identify Aβ plaques, ELISA measurement allows the
quantification of total Aβ. Using a sequential proto-
col, we separated monomeric and small oligomeric
Aβ (carbonate-soluble) from larger aggregates (guan-
idine-soluble) in whole-brain homogenates. Next, we
quantified the amount of Aβ42 and found that it was
significantly reduced in both fractions (carbonate
soluble: control 109.3 ± 21.6 ng/ml, T. gondii 31.1 ±
12.5 ng/ml, p < 0.05; guanidine fraction: control 406.9
± 79.9 ng/ml, T. gondii 132.3 ± 35.2 ng/ml, p < 0.05,
Fig. 6a).Fig. 5 Ablation of CCR2+Ly6Chi monocytes increases Aβ accumulation in T
treated with the anti-CCR2 monoclonal antibody MC-21 to specifically abla
measured 28 days post infection and after 13 days of anti-CCR2 administratio
ablation of Ly6Chi monocytes in (b) anti-CCR2 treated animals compared to (a
d28 as well as in the brain on d28 were analyzed and their percentage of live
T. gondii infection with and without monocyte ablation was measured by ELIS
levels (p values) determined by unpaired Student’s t test are indicated. *p≤ 0Recruited mononuclear cells increase proteolytic
clearance of Aβ
Along with uptake of Aβ, its proteolytic processing is
equally important. Therefore, we measured the expres-
sion of three Aβ-degrading enzymes in the brain, namely
insulin-degrading enzyme (IDE), neprilysin (NEP), and
matrix metalloproteinase 9 (MMP9), using RT-PCR, and
we observed a significant increase in the expression of
MMP9 and IDE mRNA following infection with T. gon-
dii (MMP9: 1.3 ± 0.1 fold-change over 5xFAD controls,
p < 0.01, Fig. 6b’; IDE: 1.7 ± 0.1 fold-change over 5xFAD
controls, p < 0.01, Fig. 6b”). The expression of NEP
remained unaltered (Fig. 6b, 0.94 ± 0.1 fold-change over
5xFAD controls, p > 0.6).. gondii infected 5xFAD mice. T. gondii infected 5xFAD mice were
te CCR2+Ly6Chi monocytes. a, b Ly6Chi monocytes in the blood were
n. Representative dot plots picture the gating strategy and the specific
) PBS treated animals. c, d Ly6Chi monocytes in the blood on d22 and
cells is displayed. e The amount of Aβ42 in the brains of 5xFAD mice after
A. Data (n = 4 per group) are presented as mean + SEM. Significance
.05, **p≤ 0.01
Fig. 6 T. gondii infection reduces small and large Aβ aggregates and enhances mRNA expression of the Aβ degrading enzymes IDE and MMP9 as
well as immunoproteasomal subunits. a Aβ42 in the carbonate soluble (monomeric and small oligomeric Aβ42 aggregates) and guanidine soluble
fractions (large Aβ42 aggregates) of whole-brain homogenates was measured by ELISA. Data are presented as mean + SEM. b, b’, b” Expression of
neprilysin (NEP), matrix metalloproteinase 9 (MMP9) and insulysin (IDE) in the brain was measured by RT-PCR in non-infected (n = 5) and T. gondii
infected (n = 7) 5xFAD mice. Data are presented as fold-change over non-infected 5xFAD mice in box and whisker graphs. c, c’, c” Expression of
the immunoproteasome subunits LMP2, LMP7 and MECL-1 in the brain was measured by RT-PCR in non-infected (n = 5) and T. gondii infected
(n = 7) 5xFAD mice. Data are presented as fold change over non-infected 5xFAD mice in box and whisker graphs. d, d’, d” Expression of the MMP9,
IDE and LMP7 by innate immune cells isolated and sorted from the brains of non-infected and T. gondii infected C57BL/6 mice was measured by
RT-PCR. Each sample consists of pooled cells from six animals and was measured in triplicates. Significance levels (p values) determined by unpaired
Student’s t test or Fisher’s LSD test are indicated. *p≤ 0.05, **p≤ 0.01, ****p≤ 0.0001
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proteasome system (UPS). The UPS is the major intracel-
lular protein degradation machinery and includes the pro-
teolytic subunits β1i/LMP2, β2i/MECL-1, and β5i/LMP7.
We detected a strong increase of mRNA expression for
the immunoproteasome subunits β1i/LMP2, β2i/MECL-1,
and β5i/LMP7 in whole-brain RNA from T. gondii in-
fected 5xFAD mice (β1i/LMP2: 108 ± 9 fold-change over
5xFAD controls, p < 0.0001, Fig. 6c; β2i/MECL-1: 8 ± 0.7
fold-change over 5xFAD controls, p < 0.0001, Fig. 6c’; β5i/
LMP7: 59 ± 2 fold-change over 5xFAD controls, p <
0.0001, Fig. 6c”). Interestingly, detailed investigation of
brain resident as well as recruited immune cells in T. gon-
dii infected mice revealed a prominent mRNA expression
of β5i/LMP7 in recruited mononuclear cells (Fig. 6d”) in
contrast to other Aβ degrading mechanisms. MMP9
mRNA was upregulated in activated compared to surveil-
ling microglia, but almost undetectable in recruited
mononuclear cells (Fig. 6d). IDE mRNA was similarlyexpressed across all innate immune cell populations we
investigated (Fig. 6d’). Notably, LMP7 mRNA expression
was more than twofold higher in the sorted recruited
mononuclear cells in the brain when compared to surveil-
ling or activated microglia, indicating a new mechanism of
Aβ clearance. Of note, in the chronic stage of infection
the intracellular parasites form cysts within neurons hid-
ing from the immune system, thus the analyzed cells were
not directly infected with tachyzoites.
Furthermore, we investigated which cell types are lo-
cated around the Aβ plaques in the cortex of T. gondii
infected 5xFAD mice by performing immunofluores-
cence stainings against Iba1, Ly6C, and Aβ. Due to their
general distribution in the parenchyma, Iba1+ microglia
and monocyte-derived macrophages were closely associ-
ated with Aβ plaques (Fig. 7a, b). Interestingly, Ly6C+
cells were not located directly in the vicinity of Aβ pla-
ques (Fig. 7c, d). As to that, it is important not to
confuse Ly6C+ monocytes with Ly6C expressing
Fig. 7 Microglia but not Ly6Chi monocytes are located in the vicinity of Aβ plaques. a-d show immunolabeled coronal sections from T. gondii
infected 5xFAD mice. a, b Co-labeling of Iba1 (microglia) and Aβ (plaques) reveals close interaction of microglia with plaques. a Low magnification
(20x) overview of the cortex. Scale bar, 200 μm. b Representative cortical plaque surrounded by microglial processes. 63x magnification, scale bar,
20 μm. c, d In sections co-labeled for Ly6C (Ly6Chi monocytes) and Aβ (plaques), Ly6Chi monocytes were not located in the direct vicinity of
plaques. c Low magnification (20x) overview of the cortex. Scale bar, 200 μm. d Representative cortical plaque with a nearby Ly6C+ blood vessel but
no associated Ly6Chi monocytes. 63x magnification, scale bar, 20 μm. e, f The sections were analyzed to quantify the fluorescence intensity of (e) Iba1
and (f) Ly6C in the direct environment of plaques. The black line represents the average at a given distance. AU, arbitrary units
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elongated shape. This qualitative finding was confirmed
by quantification of fluorescence intensity around plaques
(Fig. 7e, f ).
Taken together, our results show that Ly6Chi, Ly6Cint,
and Ly6Clow mononuclear cells are highly capable of re-
moving soluble Aβ peptides. While Ly6Chi monocytes
contribute significantly to this clearance, they cannot be
found in the direct vicinity of established plaques and
thus, may rather lower the general amount of Aβ to pre-
vent higher molecular weight Aβ aggregates and plaque
formation.
Discussion
In the present study, we investigated the effect of the
commonly persisting cerebral Toxoplasma infection and
resulting CNS inflammation on Aβ plaque formation in
a murine model of AD. In the following, we will first dis-
cuss the etiologic connection between T. gondii and AD
and how our results contribute to the understanding of
this connection. Second, we will address the individual
results and evaluate what we learned from this experi-
mental setup with respect to a possible treatment of AD.
Etiologic connection between T. gondii and AD
Aβ and hyperphosphorylated tau form disease promot-
ing aggregates in AD that trigger chronic cerebral in-
flammatory processes [76, 77]. Further modulation of
the chronic inflammation may occur following several
infectious diseases, which are known to induce inflam-
matory cascades in the CNS. It is well established that
certain pathogenic components modulate the course of
disease in murine β-amyloidosis models [78]. Although
the impact of particular infections during the pathogen-
esis of AD has been discussed, the underlying mecha-
nisms are especially challenging to untangle (reviewed in
[38]). In general, previous studies have found chronic or
latent infections to be associated with an increased risk
for AD (reviewed in [38]), although evidence regarding
T. gondii specifically is inconclusive [54, 55]. On the other
hand, a recent study using a mouse model of cerebral β-
amyloidosis, T. gondii infection has been associated with a
reduced risk of developing AD-like pathology [58]. Our
study provides further evidence for this notion, as we de-
tected a significant reduction in the number and volume
of β-amyloid plaques in T. gondii infected compared to
non-infected 5xFAD mice.
Despite this observed reduction in plaque deposition,
one should be cautious in concluding that T. gondii infec-
tion may protect against developing AD. In fact, while evi-
dence regarding actual disease risk is sparse and
conflicting [54, 55], latent toxoplasmosis in healthy indi-
viduals has recently been associated with subtle reductions
of cognitive performance in various tasks [79–81]. Directlytranslating this finding to the situation of human AD pa-
tients is rather difficult, considering the limitations of the
applied experimental model. Low dose infection of mice
with the parasites is a broadly used model to mimic human
chronic Toxoplasma infection [18, 23, 44, 46, 49, 82–85],
although the immune cell recruitment in mice is most
likely more pronounced than during latent chronic infec-
tion of humans. Considering that we propose the recruited
immune cells as major mediators of the beneficial effect, it
is unclear which effects are applicable to the human CNS.
Insights regarding the treatment of AD
As mentioned above, we measured decreased levels of
Aβ plaques in the brains of T. gondii infected 5xFAD
mice and the remaining plaques were also smaller in vol-
ume. These findings are consistent with the aforemen-
tioned study by Jung and colleagues, where they further
described an improved performance in behavioral tests
compared to non-infected transgenic mice [58].
We performed a more detailed investigation of the Aβ
load and detected that the general reduction of Aβ pla-
ques was paralleled by a decrease in small soluble Aβ
species. Because higher levels of soluble Aβ has previ-
ously been linked to decreased cognitive performance
[86, 87], this finding could suggest that our experimental
setup at least partially protects from cognitive decline.
Controlling the infection with T. gondii requires the
collaboration of innate and adaptive immunity [48]. Even
though there are inflammatory diseases of the CNS
which involve adaptive immune cells, such as multiple
sclerosis, the inflammation observed in AD seems to be
restricted to innate immune cells [88]. Thus, we focused
our further analysis on the contribution of the innate
compartment.
The detailed analysis of infiltrating immune cells con-
firmed the strong recruitment of innate immune cells,
particularly CD45hi CD11bhi myeloid cells, to the brains
of T. gondii infected 5xFAD mice, similar to that seen in
wildtype mice. It has been described previously by our
group that in mice chronically infected with T. gondii,
Ly6Chi monocytes migrate to the CNS and further dif-
ferentiate into Ly6Cint mononuclear cells and Ly6Clow
macrophages in order to carry out specific tasks in host
defense, such as cytokine production and Fc receptor
mediated cellular phagocytosis [18, 23].
We analyzed the contribution of these myeloid-
derived mononuclear cell subsets in the process of accu-
mulating Aβ plaques that, according to the widely
accepted view on AD pathophysiology, ultimately pro-
mote neurodegeneration.
Ex vivo phagocytosis assay most likely by an antibody-
independent mechanism revealed that all recruited
mononuclear subpopulations were able to take up sig-
nificantly more Aβ42 than microglia from non-infected
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mice. We found that Ly6Chi monocytes displayed an
even higher uptake compared to Ly6Clow cells. Compar-
ing the ability to take up Aβ42 with the ability to take up
latex spheres as previously published [23], we noted a
difference with respect to the Ly6Chi and Ly6Cint sub-
sets. While their uptake of latex spheres is very low [23],
they displayed a prominent uptake of Aβ42. Even though
our results are against the general view that Ly6Clow
cells are the most macrophage-like subset, other publica-
tions have attributed phagocytic activity to Ly6C+ mono-
cytes against parasites [89, 90]. Thus, we conclude that
uptake of latex beads and Aβ42 is mediated by different
mechanisms with diverse appearance in Ly6Chi mono-
cytes and Ly6Clow macrophages.
While neuroinflammation has been conventionally re-
ported to be detrimental and associated with several
neurological diseases [91–93], emerging research pro-
motes a more differentiated view on the roles of recruited
immune cells in homeostatic and repair mechanisms
[12, 13, 27, 94, 95]. Consistent with this concept,
there are a growing number of reports indicating the
beneficial effect of recruited immune cells in AD and
vascular amyloidosis [28–30, 96–98].
Performing the ex vivo phagocytosis assay with cells ob-
tained from both wildtype and 5xFAD mice, we also ob-
served that the relative contributions were independent of
the genotype, despite absolute values being different. As
these differences were most likely caused by the different
quantification methods, we conclude that wildtype cells
are potent Aβ clearing cells as well. Importantly, this find-
ing suggests that cells probably do not have to be pre-
exposed to Aβ to efficiently phagocytose Aβ in a possible
treatment strategy. It is somehow challenging that human
macrophages were found to be ineffective at Aβ phagocyt-
osis when derived from AD patients [99]. Nevertheless,
modulating the route of entry may provide a tool to skew
recruited monocytes towards an inflammation resolving
phenotype [22] and the capacity of these manipulated
monocytes to remove Aβ remains to be investigated, as
two studies have found that the replacement of brain resi-
dent microglia with peripheral myeloid cells does not re-
duce the Aβ burden [100, 101]. Both studies used a
similar approach to replace microglia with peripheral cells,
i. e. depletion of brain resident CD11b-expressing cells
during a 10 to 14 days intracerebral ganciclovir treatment
of CD11b-HSVTK (herpes simplex virus thymidine kin-
ase) transgenic mice [100, 101]. This treatment leads to a
one-time replacement with bone marrow-derived myeloid
cells, as opposed to the continuous influx observed in our
model of chronic cerebral T. gondii infection. Additionally,
Prokop and colleagues point out the lack of an activating
stimulus in their model, which would be able to induce
the uptake of Aβ by myeloid cells [100]. Even though thislack of stimulation is resolved in our experimental model,
finding appropriate stimuli to manipulate the cells is a
complex task, as we have to keep in mind that beneficial
and detrimental effects of monocytes and macrophages
can occur at the same time [102].
The increased amount of Aβ42 detected following
CCR2hi Ly6Chi monocyte ablation in infected 5xFAD
mice points to a causal role of these cells to Aβ clear-
ance. Our findings are supported by a report from Naert
and Rivest, who have linked the lack of Ly6Chi
(CX3CR1low CCR2+ Gr1+) monocytes to cognitive de-
cline in APPSwe/PS1 mice [65]. This hypothesis is fur-
ther strengthened by two very recent studies where
myeloid cell recruitment to the CNS was correlated
with Aβ plaque reduction [30, 103]. In a very recently
published study, Baruch and colleagues proposed a
novel treatment strategy to target AD via programmed
death-1 (PD-1) inhibition and thereby increasing the re-
cruitment of Ly6Chi monocytes to the CNS in an IFN-γ
dependent manner [104]. The proposed mechanisms
included enhanced cellular uptake and degradation.
Furthermore, Savage et al. detected phagocytic cells
directly associated with plaques, and the CD45hi status
of these cells suggested their myeloid origin [105]. Only
short-term recruitment of monocytes did not alter
plaque deposition as seen in a mouse model of trau-
matic brain injury [106].
Having confirmed Ly6Chi monocytes as key contribu-
tors to Aβ removal in our model, we were interested if
they migrate into the parenchyma to “attack” Aβ plaques
like previous reports have shown [28, 103, 107]. How-
ever, CCR2+ Ly6C+ monocytes were not located in the
vicinity of plaques in our experiments. Therefore, we
propose that the low plaque burden in the applied ex-
perimental model is due to Ly6Chi monocytes’ increased
capacity to remove soluble Aβ rather than due to direct
removal of established plaques. In addition, monocyte-
derived Ly6Clow macrophages upregulate F4/80 and
Iba1, and can be located adjacent to the plaques, simi-
larly to resident microglia.
It has to be carefully investigated, at which stages of
disease the recruitment of monocytes and subsequent
removal of Aβ is beneficial and can delay the onset of
disease, and at which stages the cascade triggered by Aβ
is already on its way and additional cell recruitment po-
tentially worsens neuroinflammation [108]. Our data
from old animals provides evidence that the ability of
freshly recruited immune cells to remove Aβ persists at
later stages of experimental amyloidosis.
Searching for a mechanism mediating Aβ uptake, we
analyzed the expression of cell surface markers related
to phagocytosis on CD11bhi Ly6G− myeloid-derived cells.
The measurements revealed intermediate levels of
TREM2, CD36 and SCARA1 on Ly6Chi monocytes and
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Recent reports of a correlation between genetic TREM2
mutation and AD [109, 110], along with experiments
pointing out the anti-inflammatory and phagocytosis-
enhancing role of TREM2, have drawn the attention to-
wards this molecule [111–114]. We detected that
monocyte-derived Ly6Clow macrophages expressed high
levels of TREM2, in contrast to Ly6Chi monocytes. This
result underlines that, besides TREM2, other factors
may determine the capacity of immune cells such as
monocytes to phagocytose Aβ. Several studies have sug-
gested that CD36 expression is associated with Aβ up-
take [76, 115, 116], consistent with the CD36 expression
of Ly6Clow monocyte-derived macrophages. Moreover, the
lower expression of CD36 detected on Ly6Chi monocytes
may be beneficial because of less harmful pro-inflammatory
CD36-Aβ interaction [117–120]. Frenkel and colleagues
had shown that SCARA1 (and not CD36) mediates phago-
cytosis of Aβ [118]. However, similar to TREM2 and CD36,
SCARA1 expression was not a reliable predictor of the Aβ
phagocytic capacity of each myeloid-derived mononuclear
cell subset in our model.
Recent research highlights the importance of proteolytic
Aβ degradation. Several enzymes are known to digest Aβ,
including MMP9 and IDE, but the contribution of each
enzyme is crucial. Removal of only one can result in sig-
nificantly increased cerebral Aβ levels [121], and overex-
pression leads to decreased Aβ loads [121–123]. We
found bothMMP9 and IDE upregulated significantly upon
T. gondii infection in 5xFAD mice.
MMP9 is one of several matrix metalloproteinases that
have been implicated in Aβ degradation and administra-
tion of an MMP inhibitor resulted in increased Aβ loads
[121]. Activation of MMPs has to be regarded carefully
as well, as a recent study has shown that Aβ increases
the permeability of the BCSFB by activation of MMPs
[124]. Even though Brkic and colleagues found the big-
gest changes for MMP3 expression, the contribution of
other MMPs cannot be ruled out. IDE hydrolytically
cleaves Aβ [125], and the significantly increased expres-
sion of IDE, particularly in conjunction with the simultan-
eously increased MMP9 expression, therefore most likely
promoted the enhanced degradation of Aβ in T. gondii in-
fected 5xFAD mice, when compared to non-infected con-
trols. Upregulation of IDE may be a compensatory
mechanism, since insulin has been shown to stimulate the
growth of T. gondii in vitro [126], and increased Aβ deg-
radation could be a beneficial secondary effect.
In addition, intracellular control of protein homeostasis
is mediated by the ubiquitin-proteasome system, whereby
proteasomes represent the proteolytically active part. Dys-
function of the UPS has been shown to be an early event
in Alzheimer’s disease, suggesting that proteasomes may
be unable to properly degrade ubiquitin-tagged proteins[127]. Immunoproteasomes are specific proteasome iso-
forms that have incorporated the immunosubunits β1i/
LMP2, β2i/MECL-1, and β5i/LMP7. Previous data point
to an important role of immunoproteasomes in the rapid
degradation of oxidant-damaged proteins, thus expression
of immunoproteasomes may be beneficial in Aβ clearance
[128]. Indeed, recently published data indicate that react-
ive glia exhibit induced immunoproteasome expression
and activation in the cortex of a plaque pathology mouse
model [129]. On the other hand, β5i/LMP7-deficiency has
been shown to result in attenuation of lymphocytic chor-
iomeningitis virus (LCMV)-induced meningitis [130, 131].
Notably, our data presented here demonstrate the most
prominent β5i/LMP7 expression in recruited mono-
nuclear cell subsets, indicating that high immunoprotea-
some expression in monocytes and their progeny are
associated with their enhanced capacity in Aβ degradation
and suggesting a novel mechanism of Aβ elimination.
However, the exact engagement of the UPS in the men-
tioned processes requires detailed investigation in forth-
coming experiments.
Conclusions
Taken together, our results demonstrate that mono-
nuclear cell recruitment to the brain upon chronic
T. gondii infection leads to reduced plaque burden by
promoting phagocytosis of soluble Aβ42 and enhanced
proteolytic degradation. This aspect is especially critical
in a situation where resident microglia are dysfunctional
and fail to control amyloid plaque deposition [67, 132].
Chronic T. gondii infection acts as a strong immuno-
logical stimulus, possibly even overcoming the impaired
phagocytic capacities of monocytes/macrophages as ob-
served in AD patients [99]. In the light of a future treat-
ment option, a recent study by Neal and Knoll presented
data from mice showing that infection with T. gondii
protects from bacterial infection with Listeria monocyto-
genes by recruitment of Ly6Chi monocytes. Further ex-
periments revealed that only application of a component
of T. gondii is sufficient to mediate the resistance [133].
This method of recruiting monocytes may be interesting
to consider, as our results suggest a promising candidate
mechanism for the protective effect, namely increased
phagocytosis and degradation of Aβ.Additional file
Additional file 1: Figure S1. Ex vivo Aβ42 uptake by cells from wildtype
C57BL/6 mice. Ex vivo phagocytosis assay was performed with mononuclear
cells isolated from C57BL/6 mouse brains. Populations were gated as
described in Fig. 3a and Aβ42 uptake was quantified using imaging flow
cytometry. Bars indicate the median fluorescence intensity (MFI) of each
population and data are displayed as mean + SEM (n = 5). Significance levels
(p values) determined by Fisher’s LSD test are indicated. ns, not significant,
*p≤ 0.05, **p≤ 0.01, ****p≤ 0.0001. (TIF 144 kb)
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